Government advisory group Zorginstituut Nederland recommended that Novartis' spinal muscular atrophy (SMA) drug Zolgensma should not be included in the basic insurance package unless the price is halved, as reported DutchNews.nl.
In addition, Novartis should also agree to payment on the basis of the actual results, the institute said.
The drug costs €1.9m per treatment, with SMA affecting around 20 children in the Netherlands a year
The institute estimates that if the cost were halved, the drug would add around €11 million to the Dutch healthcare budget a year.
To read more NewsPoints articles, click here.